Receptors & signaling

A receptor is a protein that recognizes a signal and can help a cell respond. A molecule that activates it is called an agonist. The response depends on the receptor and the cell's internal machinery. Researchers can measure binding or signaling without measuring a clinical benefit. A mechanism explains how an effect might occur; an outcome study asks whether that effect occurred in the setting that matters. [1] [2]

What you will learn

Trace a signal from a cell-surface receptor through an intracellular relay.
Distinguish receptor affinity, potency and maximum assay response.
Explain why a response in one cell system does not by itself predict a clinical outcome.

Start with recognition and response

A signaling molecule is often called a ligand when discussing what it binds. Many peptide signals act through receptors at the cell surface. The receptor can connect an outside event to changes inside the cell, so the peptide does not necessarily need to enter the cell to start a response. Receptors are not identical locks with one universal downstream effect. [2] [1]

An agonist initiates receptor activity. An antagonist can occupy a receptor and interfere with an agonist's action without initiating the same response. A partial agonist produces a smaller maximum response than a full agonist in the system being examined. These words describe behavior in a receptor system; they do not rank overall clinical usefulness or establish that a molecule is safe. [2]

A signal is relayed

G-protein-coupled receptors are one important receptor family. An activated receptor changes the activity of a G protein on the inside of the cell. The G protein can influence an enzyme or ion channel, and the effect can spread through intracellular signals. Cyclic AMP, often written cAMP, is one such second messenger. It is a molecule involved in the relay, rather than a second peptide acting outside the cell. [3]

A relay can amplify a signal because one activated step can affect many molecules downstream. It also has mechanisms that limit or turn off the response. Other receptor families use different machinery. The term signaling pathway is therefore a description of connected events. It is helpful to know the named pathway, but the label alone does not tell you how large, durable or useful the response is. [3]

Binding, potency and response are different questions

Affinity describes how tightly a ligand binds its receptor. Potency concerns how much of a ligand is needed to produce a specified response in an assay. Efficacy in receptor pharmacology concerns the response an agonist can produce in that system. Clinical efficacy asks about a treatment's effects in people. The shared word can create confusion, so read the measurement and context before treating an impressive receptor result as a clinical conclusion. [4] [2]

An EC50 is the concentration that produces half of the measured maximum response under the assay's conditions. It is not a recommended exposure for a person. Comparing EC50 values requires compatible endpoints and experimental systems. A cell assay with many receptors can differ from a tissue with another receptor density and signaling machinery. The number has meaning inside its methods. [4]

The cell changes the answer

The same signal can produce different responses in different kinds of cell, even when the receptor is the same. The internal proteins, parallel signals and cellular state help determine the response. This explains why a receptor target is a useful starting point for a profile but an incomplete prediction of a whole-body outcome. A pathway includes the receiving cell, not only the molecule arriving at it. [1]

Use this when reading a paper

Name the observation precisely. “Bound the receptor,” “increased cAMP,” and “changed a clinical outcome” are three different statements. A paper may connect them, but you should be able to point to the experiment supporting each connection. If only the signaling assay was performed, retain that narrower wording. It explains the finding without pretending the later steps were observed. [3] [4]

Then identify the assay's cells, receptor and measured response. This habit is especially useful when comparing peptides described as single, dual or triple agonists. The target list gives a map of proposed biology; it does not account for every tissue, exposure or interaction in a person. Use mechanism to understand the question, then read the human trial for its own population and endpoint. [1] [2]

Common questions

Does stronger receptor binding mean a better treatment? Binding is one property. Response, exposure, harms and the clinical question also matter. [2] [4]

What is a second messenger? An intracellular signal molecule, such as cAMP, that helps relay a signal initiated at a receptor. [3]

Why can two cell studies differ? They may use different cells, receptor abundance, conditions or measurements. Those differences belong in the comparison. [1] [4]

Worked example: compare two invented signaling curves

Assume an invented cell assay measures cAMP after stimulation by two hypothetical agonists, A and B. Both are tested in the same cells with the same receptor and measurement procedure. A reaches half of its own maximum response at a lower concentration than B. Under these assumed conditions, A has the lower EC50 for that response. The numbers in a real comparison would need the actual assay methods. [4]

Now suppose B reaches a larger maximum cAMP response. The first observation concerns potency, while the second concerns maximum response in this system. Neither observation tells you directly which molecule binds more tightly, because affinity is a separate binding property. Nor do these curves measure how much of either molecule will reach a tissue in a person. [4] [2]

The justified summary names both results and stops at the assay. To investigate a clinical claim, researchers would need relevant exposure, outcome and harms data. This is why a lower EC50 can be scientifically useful without serving as a ranking of treatments. [4] [5]

Check your understanding

A peptide increases cAMP in cultured cells. Must the peptide have entered the cells?

Show explanation

No. Binding at a cell-surface receptor can activate an intracellular relay that changes cAMP. The assay would need separate evidence to establish entry of the peptide itself. [3] [6]

In the invented assay, A has a lower EC50 but B has a higher maximum response. Which is “better”?